The life expectancy of scleroderma patients is more difficult to predict and cannot be generalized. It is mainly related to the degree of sclerosis of the individual’s skin and internal organs. If the disease is treated early and aggressively, with no accumulation of internal organs, it does not affect the life expectancy; if it is detected late, those with severe conditions involving the heart, lungs, and kidneys may have a shorter survival time. Scleroderma, also known as systemic sclerosis, is a chronic disease of unknown cause, characterized by diffuse fibrosis, degenerative changes and vascular abnormalities in the skin, joints and internal organs. Diagnosis through laboratory tests such as blood tests, serologic tests, skin biopsy, and chest CT examination and treatment for complications can effectively control the progression of the disease, slow down and reduce the degree of visceral involvement, improve the quality of life of patients, and prolong their lives. Patients with scleroderma who are treated early and aggressively with no accumulation of internal organs do not affect their life expectancy; those with severe conditions are likely to have a shorter survival time if they are detected late and without effective intervention and if the lesions involve the heart, lungs, and kidneys. It is recommended that patients with scleroderma should go to the rheumatology and immunology department in a timely manner, and be actively treated under the guidance of the doctor, so as not to delay the condition.